Adelaide Research & Scholarship: Search

Search

Search:
for

Current filters:

Start a new search

Add filters:

Results/Page | Sort items by In order Authors/record

Results 11-20 of 22 (Search time: 0.003 seconds).

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy	Angelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
	2014	Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling	Pishas, K.; Neuhaus, S.; Clayer, M.; Schreiber, A.; Lawrence, D.; Perugini, M.; Whitfield, R.; Farshid, G.; Manavis, J.; Chryssidis, S.; Mayo, B.; Haycox, R.; Ho, K.; Brown, M.; D'Andrea, R.; Evdokiou, A.; Thomas, D.; Desai, J.; Callen, D.; Neilsen, P.
	2012	Death adder envenoming causes neurotoxicity not reversed by antivenom - Australian snakebite project (ASP-16)	Johnston, C.; O'Leary, M.; Brown, S.; Currie, B.; Halkidis, L.; Whitaker, R.; Close, B.; Isbister, G.; Nagree, Y.; Ker, F.; Greene, S.; Taylor, M.; Macrokanis, C.; Wilke, G.; Coulson, A.; Barnes, C.; Bonni, R.; Whitake, R.; Halkidis, L.; Isbiste, G.; et al.; de Silva, J.
	2015	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets	Yeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Trotman, J.; Forsyth, C.; Taper, J.; Ross, D.; Beresford, J.; Tam, C.; et al.
	2015	Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia	Weickert, T.; Weinberg, D.; Lenroot, R.; Catts, S.; Wells, R.; Vercammen, A.; O'Donnell, M.; Galletly, C.; Liu, D.; Balzan, R.; Short, B.; Pellen, D.; Curtis, J.; Carr, V.; Kulkarni, J.; Schofield, P.; Weickert, C.
	2012	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer	Khattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
	2011	Efficacy of α-lactalbumin and milk protein on weight loss and body composition during energy restriction	Soenen, S.; Hochstenbach-Waelen, A.; Westerterp-Plantenga, M.
	2010	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)	Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
	2011	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study	Kotasek, D.; Tebbutt, N.; Desai, J.; Welch, S.; Siu, L.; McCoy, S.; Sun, Y.; Johnson, J.; Adewoye, A.; Price, T.
	2010	Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study	Cortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.